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The androgen receptor (AR) is a ligand-dependent
transcription factor that has an essential role in the
normal growth, development, and maintenance of the
prostate gland. The AR is part of a large family of steroid
receptors that also includes the glucocorticoid, proges-
terone, and mineralocorticoid receptors. Steroid recep-
tor family members share significant homology at their
DNA and ligand-binding domains. However, these re-
ceptors exhibit a high degree of sequence variability at
their NH2-terminal domain, which suggests the possibil-
ity of receptor-specific interactions with co-regulator
proteins. Transcriptional co-regulators that interact
with the AR may have a role in defining AR activity and
may be involved in directing AR-specific responses.
Here we have identified Ran-binding protein in the
microtubule-organizing center (RanBPM) to be a novel
AR-interacting protein by yeast two-hybrid assay and
have confirmed this interaction by glutathione S-trans-
ferase- and His-tagged pull-down assays. In addition,
transient overexpression of RanBPM in prostate cancer
cell lines resulted in enhanced AR activity in a ligand-
dependent fashion. Glucocorticoid receptor activity was
also enhanced when RanBPM was overexpressed,
whereas estrogen receptor activity remained un-
changed. These data demonstrate that RanBPM inter-
acts with steroid receptors to selectively modify their
activity.
The androgen receptor (AR)1 is a ligand-dependent tran-
scription factor that belongs to a family of steroid receptors
along with the glucocorticoid (GR), progesterone, and miner-
alocorticoid receptors. These steroid receptors share similar
domain structures and mechanism of action. Steroid receptors
including the AR have three functional domains: a COOH-
terminal ligand-binding domain (LBD), a central DNA-binding
domain (DBD), and an NH2-terminal domain (1). In the ab-
sence of androgens, the AR is localized to the cytoplasm in an
inactive complex that includes heat shock proteins (HSP).
Upon binding to its cognate ligand, the AR undergoes a confor-
mational change that results in a more compact and stable
form of the AR. The activated AR dissociates from HSPs and
translocates to the nucleus where it interacts with consensus
DNA sequences as a homodimer to influence transcription of
downstream genes (2). The estrogen receptor (ER) belongs to a
different steroid receptor subfamily because it resides predom-
inantly in the nucleus, even in its unliganded form, and does
not require translocation across the nuclear membrane follow-
ing activation (3). There are two major transactivation regions
in the AR. 1) The activation function-1 (AF-1) domain is found
at the NH2 terminus. 2) AF-2 is located in the LBD. AF-2 is a
weak transactivator that is dependent on the presence of an-
drogens for its activation. AF-1, on the other hand, is capable of
ligand-independent transactivation, and fragments of the AR
that contain AF-1 show high levels of transcriptional activity
when ectopically expressed in cell lines that are devoid of
endogenous AR (4, 5).
Upon DNA binding, AR recruits components of the basal
transcriptional machinery and influences either the up-regula-
tion or down-regulation of gene expression. The exact mecha-
nism of AR-specific gene expression is not fully understood.
Each steroid receptor regulates unique sets of genes. However,
in vitro assays have shown that these receptors recognize sim-
ilar DNA sequences known as steroid response elements. These
elements are comprised of a palindrome that contains two
half-sites based on the 5-TGTTCT-3 motif that are separated
by a three nucleotide spacer (6). Detailed analysis has demon-
strated that both GR and AR bind with highest affinity to a
steroid response element that has an imperfect palindrome,
5-GGTACAnnnTGTTCT-3 (7). The quandary is that although
activated steroid receptors bind to highly homologous response
elements on DNA, they still demonstrate an ability to regulate
the expression of unique gene sets.
There are several mechanisms by which receptors can spe-
cifically regulate gene expression. One mechanism suggests
that co-regulatory proteins interact with steroid receptors to
direct their activity. The search for AR-specific co-regulatory
molecules has led to the identification of several AR-interacting
proteins. Early studies identified ARA70/ELE1 as a ligand-de-
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pendent co-activator of AR (8). Subsequently, CREB-binding
protein/p300, which has histone acetyltransferase activity, was
also shown to interact with AR and enhance receptor activity in
prostate cells (9). More recent AR-interacting proteins that
have been identified include -catenin (10), caveolin (11),
BAG-1L (12), SMAD3 (13), cyclin D1 (14), and several others.
These proteins have been shown to either positively (caveolin
and BAG-1L) or negatively (SMAD3 and cyclin D1) affect AR
transactivation.
Identification of proteins that specifically interact with the
AR has been a challenge because the AR and other steroid
receptors share a high degree of sequence homology at their
DBD and LBD. The DBD of human AR shares as much as 80%
homology with that of progesterone receptor and over 70% with
GR (15). The LBD of the steroid receptors are highly homolo-
gous as well with up to 55% similarity at the amino acid level.
Therefore, many co-regulatory proteins that interact with the
AR at the LBD and DBD are promiscuous in their ability to
interact with and influence activity of other steroid receptors. A
report by Alen et al. (16) has demonstrated that ARA70 is not
specific to the AR and that this protein interacts with the ER
and GR as well. Likewise, the steroid receptor co-activator-1/
NCoA1, which is the founding member of the p160 family of
transcriptional co-activators, interacts indiscriminately with
the LBD of steroid receptors to enhance activity (17). Other
members of the p160 family such as TIF-2/GRIP-1 enhance AR,
GR and ER activity alike (18).
Nevertheless, steroid receptor family members show the
greatest degree of sequence variability at the NH2-terminal
domain (15%). Little is known regarding the role of the NH2-
terminal domain in AR transactivation. Therefore, we used an
NH2-terminal fragment of the AR, which is devoid of transcrip-
tional activity (AR1–232), as bait in a yeast two-hybrid assay,
and RanBPM was identified as an AR-interacting protein. Al-
though RanBPM was initially described as a 55-kDa protein
(BPM55), a subsequent report has shown it to be a 90-kDa
protein (BPM90) (19, 20). Here we demonstrate that the larger
form of RanBPM, BPM90, is able to bind to multiple domains of
the AR and that this interaction occurs in vivo. Furthermore,
overexpression of RanBPM in prostate cancer cell lines shows
that RanBPM can enhance AR transactivation. This property
of RanBPM does not appear to be exclusive to the AR because
BPM90 also enhances GR activity, although neither ER- nor
ER- activity is affected. These experiments clearly demon-
strate that RanBPM is capable of interacting with and modi-
fying the activity of selective steroid receptors.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid Screening—A 696-bp fragment coding for the first
232 amino acids of the human AR (AR1–232) was cloned into the BamHI
site of the pGBT9 vector for expression as a fusion protein with the
GAL4 DBD (Clontech). A cDNA library made from normal human
prostate tissue that was fused to the transactivation domain of GAL4 in
the pACT2 expression vector was used for screening (Clontech). Expres-
sion plasmids were transformed into the Y190 yeast strain, and trans-
formants were selected on SD minimal medium lacking tryptophan,
leucine, and histidine. Clones that grew on minimal medium agar
plates were subjected to -galactosidase assays by colony filter-lift
according to the manufacturer’s instructions. Clones that tested posi-
tive for -galactosidase were sequenced using Big Dye Terminator cycle
sequencing reactions (Applied Biosystems) and were then compared
with known sequences available in GenBankTM.
Plasmid Construction—The full-length RanBPM expression vector,
pcDEB-BPM90, and empty vector, pcDEB, were provided by Dr. H.
Nishitani (Kyushu University) (20). The longest RanBPM library clone
that was isolated in the yeast two-hybrid assay contained a 2152-bp
fragment that coded for amino acids 148–729 of BPM90 and the 3-
untranslated region. This fragment of BPM90, herein referred to as
BPML, was cloned into the pRC/cytomegalovirus (CMV) mammalian
expression vector (Invitrogen) in which transcription is driven by the
CMV promoter. BPML was cloned in-frame with an upstream ATG for
translation initiation and a Kozak sequence to enhance translation
efficiency.
The NH2-terminal region of the human AR spanning the NH2-
terminal domain and DBD (hAR1–646) was generated by PCR and
cloned into the multiple cloning site of pRC/CMV for expression in
mammalian cells. The full-length rat AR cDNA was expressed from
the pRC/CMV mammalian expression plasmid, pCMV/AR6 (21). The
rat glucocorticoid receptor was expressed from the pGR mammalian
expression vector as described elsewhere (22). The human ER- expres-
sion vector (pSVMT:wER) has also been described previously (23). The
pcDNA4/HisMax-hER1 vector (a gift from Dr. L. Murphy, University
of Manitoba) was used for the expression of human ER- in mammalian
cells.
Northern Blot Analysis—Multiple tissue Northern blots (Clontech)
were probed with [32P]dCTP-labeled RanBPM cDNA. Poly(A) RNA was
prepared from the LNCaP, PC3, MCF7, and HeLa cell lines using an
Oligotex mRNA kit (Qiagen). For the Northern blot, 5 g of poly(A)
RNA were separated by electrophoresis on a 1% agarose gel with 30%
formaldehyde and transferred to a Biodyne B nylon membrane (Pall
Corporation) by capillary action in 10 mM NaOH. The membrane was
hybridized with a [32P]dCTP-labeled 1100-bp cDNA fragment coding for
RanBPM. Glyceraldehyde-3-phosphate dehydrogenase was used to nor-
malize the loading of poly(A) RNA.
GST and His-tag Pull-down Assay—Various NH2-terminal and DBD
fragments of the human AR (AR1–232, AR1–559, and AR559–646) and a
COOH-terminal fragment of rat AR (ARDBD/LBD) were cloned into the
pGEX vector (Amersham Biosciences) for expression as GST fusion
proteins. GST fusion proteins were expressed in the BL21 Escherichia
coli strain and purified as described previously (5). Radiolabeled Ran-
BPM protein was prepared from the pRC/CMV-BPML vector using the
Quick Coupled T7 TNT in vitro transcription/translation kit (Promega
Corporation) in the presence of [35S]Met. Equimolar amounts of GST-AR
fusion protein coupled to glutathione-agarose beads were incubated with
radiolabeled RanBPM at 4 °C for 2 h in binding buffer (20 mM HEPES, pH
7.6, 150 mM KCl, 5 mM MgCl2, 1 mM EDTA, 0.05% Nonidet P-40). Beads
were washed four times with binding buffer, and bound proteins were
eluted into protein sample buffer (2% SDS, 5% -mercaptoethanol) for
analysis by SDS-PAGE followed by autoradiography.
A fragment spanning the NH2-terminal domain and DNA-binding
domain of the AR (AR1–646) was cloned into the pTrcHisC vector (In-
vitrogen) for expression with an NH2-terminal His tag, which consists
of six histidine residues in tandem. His-tagged proteins were expressed
in bacteria and purified using the nickel-nitrilotriacetic acid-agarose
column according to the manufacturer’s protocol (Qiagen). [35S]Met-
RanBPM fragments were incubated with His-AR1–646 at 4 °C for 4 h in
binding buffer (see above). His-AR1–646 was immunoprecipitated using
an anti-His antibody (Qiagen) as described below.
Cell Culture and Transfection—PC3, HeLa, and MCF7 cells were
maintained in Dulbecco’s modified Eagle’s medium (Sigma) supple-
mented with 5% fetal bovine serum (FBS) (Invitrogen) at 37 °C in 5%
CO2. The LNCaP prostate carcinoma cell line was cultured in RPMI
1640 medium containing 5% FBS. For transient transfection, 3  105
cells were seeded in six-well plates and were transfected the following
day using Lipofectin reagent (Invitrogen) as described previously (24).
Transfection occurred for 16 h at 37 °C. Following transfection, cells
were re-fed with fresh medium containing 5% dextran-coated charcoal-
stripped FBS  1 nM R1881, 10 nM dexamethasone (Dex), 10 nM E2 or
vehicle alone and incubated at 37 °C for an additional 24 h. After
induction with hormone, cells were harvested and lysed in passive lysis
buffer (Promega Corporation) for luciferase assay and for Western blot
analysis.
Immunoprecipitation and Western Blotting—LNCaP cells were
grown to 80% confluency in RPMI 1640 medium  5% FBS. Cells were
then cultured in RPMI 1640 medium containing 5% dextran-coated
charcoal-stripped FBS for 16 h at 37 °C. The following day, cells were
induced in the presence or absence of 10 nM R1881 for 4 h at 37 °C
before scraping and lysis in radioimmune precipitation buffer (150 mM
NaCl, 50 mM Tris-Cl, pH 7.5, 1% Nonidet P-40, 0.5% sodium deoxy-
cholate, 0.1% SDS). Whole cell extracts (1 mg of protein) were incubated
with a polyclonal rabbit anti-AR antibody or with normal rabbit IgG as
a negative control (Santa Cruz Biotechnology, Inc.). Immunocomplexes
were pulled down using protein A/G-agarose beads (Santa Cruz Bio-
technology, Inc.) and washed four times with radioimmune precipita-
tion buffer. After the final wash, proteins were solubilized in SDS
sample buffer and analyzed by Western blot.
Western blots were carried out as described previously (21). Protein
samples were resolved on a polyacrylamide gel and transferred to a
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polyvinylidene difluoride membrane (Millipore). Membranes were
blocked in TBS (20 mM Tris-Cl, pH 7.6, 137 mM NaCl) with 5% skim
milk. Blots were incubated with appropriate primary antibody, diluted
to 2 g/ml in TBS 5% milk for 4 h at room temperature, washed three
times in TBS  0.5% Tween 20, and then incubated for 45 min
in horseradish peroxidase-conjugated secondary antibody (1:10,000)
(Santa Cruz Biotechnology, Inc.). Blots were developed using the
ECL chemiluminescence kit (Amersham Biosciences).
Transcription Assays—AR and GR constructs were co-transfected
with the pARR3-tk-Luc reporter construct in which the promoter has
three androgen response regions (ARRs) in tandem (5). In addition, the
prostate-specific antigen (PSA) and probasin (PB) luciferase reporter
constructs were used to determine transcriptional activity of the AR (4,
24). ER expression vectors were co-transfected with the pERE-Luc
reporter plasmid as described previously. The pERE-Luc plasmid con-
tains a single vitellogenin estrogen response element upstream of the
thymidine kinase (TK) promoter.2 Transfected cells were incubated in
the presence or absence of hormone at 37 °C for 24 h prior to analysis.
Transfection efficiency was normalized using the Renilla luciferase
expression vector, pRL-TK (Promega Corp.). Firefly and Renilla lucif-
erase activities were assayed with the Dual Luciferase assay kit (Pro-
mega Corp.). 20 l of cell lysate were analyzed for luciferase activity
using MicroLumiatPlus luminometer (EG&G Berthold).
RESULTS
RanBPM Interacts with the NH2 Terminus of AR in Yeast—
A fragment coding for the first 232 amino acids of the AR
(AR1–232) was used as bait in a yeast two-hybrid assay to screen
a human prostate library for interacting proteins. Over 3 105
transformants were screened on selective media, and positive
clones were identified by -galactosidase assay. Sequence anal-
ysis of three independent positive clones revealed a gene that
was highly homologous to a known human protein, RanBPM
(GenBankTM accession number AB055311) (19). Both 55- and
90-kDa forms of RanBPM have been reported in the literature
and are referred to as BPM55 and BPM90, respectively (19,
20). Sequences isolated from the three library clones isolated by
the yeast two-hybrid assay had sequences upstream of the
published BPM55 translation start codon (Fig. 1). The longest
sequence of the three library clones (ARBP1) was 2346 bp in
length and coded for a protein from amino acid 148 of BPM90
to the termination codon. This fragment is referred to as BPML.
RanBPM Interacts with AR in Vitro and in Vivo—To confirm
the interaction between RanBPM and AR that was identified
by yeast two-hybrid screening, various AR constructs were
expressed as GST fusion proteins and coupled to glutathione-
agarose beads for use in GST pull-down assays. The 2346-bp
fragment from ARBP1 (BPML) was cloned into pRC/CMV to
allow for in vitro transcription/translation from the T7 pro-
moter. [35S]Methionine-labeled BPML protein was allowed to
interact with the GST-AR fusion proteins and analyzed by
SDS-PAGE followed by autoradiography. As seen in Fig. 2A,
RanBPM interacts with the 232-amino acid fragment that was
originally used as bait in the yeast two-hybrid screen (AR1–232)
(Fig. 2A, lanes 3 and 4). Equimolar amounts of AR-GST fusion
proteins were used to determine relative binding between Ran-
BPM and various domains of AR, and the results show that
RanBPM interacts most strongly with the DBD (AR559–646)
(Fig. 2A, lane 2). In addition, RanBPM interacts with the AR
fragment that spans the DBD and LBD (ARDBD/LBD) (Fig. 2,
lane 5). However, presence of the LBD does not enhance inter-
action, which suggests that the LBD does not have additional
domains for RanBPM binding.
To assess the relevance of this interaction in vivo, we per-
formed a co-immunoprecipitation assay using LNCaP cell ly-
sates. The LNCaP prostate carcinoma cell line expresses high
levels of functional AR and displays androgen-dependent gene
expression activity. Cells were treated for 4 h with 10 nM R1881
or with vehicle alone prior to preparation of protein lysates.
Whole cell lysates were immunoprecipitated with normal rab-
bit IgG as a negative control (Fig. 2B, lanes 3 and 5) or with an
antibody that recognizes the COOH terminus of the AR (lanes
4 and 6) (Santa Cruz Biotechnology, Inc.). Protein complexes
were pulled down with protein A/G coupled to agarose beads.
Proteins of the AR complex were resolved by SDS-PAGE prior
to Western blotting with an anti-BPM90 antibody (provided by
Dr. H. Nishitani). A 90-kDa protein that is seen in the input
lanes (Fig. 2B, lanes 1 and 2) is BPM90. The results in Fig. 2B
show that BPM90 interacts with AR specifically in the presence
of hormone (lanes 3–6). We confirmed that AR was pulled-down
in this assay by blotting the same membrane with an antibody
that recognizes the NH2 terminus of the AR (Affinity BioRe-
agents) (Fig. 2B).
The NH2 Terminus of RanBPM Is Essential For interaction
with AR—RanBPM encodes a putative SPRY domain at the
NH2 terminus (Fig. 1) (19). This domain has been implicated in
protein-protein interactions. To determine the importance of
the SPRY domain, His-tag pull-down assays were carried out to
map the interacting domains between RanBPM and the AR.
Radiolabeled COOH-terminal truncations of RanBPM were
generated by restriction digest of the pRC/CMV-BPML vector
with EcoRI or NdeI followed by in vitro transcription/transla-
tion in the presence of [35S]methionine. The truncated Ran-
BPM proteins (BPM148–408 and BPM148–251) were incubated
with purified recombinant His-tagged AR1–646, which includes
the NH2-terminal domain and DBD. An antibody that recog-
nizes the His-tag (Qiagen) was used to immunoprecipitate AR
and its interacting proteins. After sufficient washing, samples
were eluted into protein sample buffer, resolved by SDS-PAGE,
and analyzed by autoradiography. Fig. 2C, Input lanes, show
that radiolabeled proteins have molecular masses of 64, 28, and
11 kDa (BPML, BPM147–408, and BPM147–251, respectively).
Both BPML and the truncated peptide generated by EcoRI
digest, BPM147–408, interacted with the AR (Fig. 2C, top and
2 J. L. Ralph, M. C. Orgebin-Crist, J.-J. Lareyre, and C. C. Nelson,
manuscript in preparation.
FIG. 1. Amino acid sequence of BPM90 (GenBankTM accession
number BAB62525). AR1–232 was used as bait to screen a normal
prostate cDNA library for interacting proteins. Three independent
cDNA clones coded for RanBPM. The underlined portion shows the
protein encoded by the longest cDNA sequence that was isolated (herein
referred to as BPML). The asterisk denotes the translation start site of
BPM55 (GenBankTM accession number BAA23216). Shaded sequence is
the putative SPRY domain.
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middle panels). However, BPM147–251 in which the SPRY do-
main is disrupted was no longer able to interact with AR (Fig.
2C, bottom panel). This finding agrees with yeast two-hybrid
results in which -galactosidase activity and, therefore, inter-
action with AR1–232 are lost when an NH2-terminal truncation
of RanBPM, which does not have a complete SPRY domain, is
used as bait (data not shown).
RanBPM Is Ubiquitously Expressed—To determine expres-
sion levels of RanBPM, a [32P]cDNA probe was generated from
the ARBP1 yeast two-hybrid library clone and hybridized to a
multiple tissue Northern blot (Clontech). This Northern blot
allows for analysis of RanBPM expression in several different
tissue types. Fig. 3A shows that RanBPM is expressed as a
2.9-kb transcript in multiple different tissue types. High levels
of RanBPM message are seen in the prostate and ovaries, and
highest levels of expression are observed in the testes (lanes 3,
5, and 4, respectively).
RanBPM expression levels were determined for various can-
cer cell lines by both Northern and Western blots (Fig. 3, B and
C). Cell lines that were used included the ovarian carcinoma
HeLa cell line from which BPM90 was first identified, two
prostate cancer cell lines, PC3 and LNCaP, and the MCF7
breast cancer cell line. Both Northern and Western blots show
that RanBPM is highly expressed in all of the cell lines. In Fig.
3C, the 90-kDa protein seen in lanes 1–4 is BPM90. Although
BPM90 is expressed in all of the cell lines tested, the highest
levels were observed in HeLa cells (lane 4). PC3 and MCF7
cells expressed lower levels of BPM90 as compared with the
LNCaP cell line (compare lanes 1 and 3 with lane 2). The
membrane was probed with an antibody for -actin (Sigma)
to demonstrate that loading efficiency was consistent in all
lanes (Fig. 3C).
RanBPM Enhances the Activity of the Androgen Receptors—
Our results have demonstrated that RanBPM interacts with
FIG. 2. RanBPM interacts with the NH2-terminal domain and
DBD of the AR. A, [35S]Methionine-labeled BPML was allowed to
interact with GST, GST-AR559–646, GST-AR1–232, GST-AR 1–559, and
GST-ARDBD/LDB (lanes 1–5, respectively) coupled to glutathione-agarose
beads at 4 °C overnight. Proteins were eluted from washed beads with
protein sample buffer and resolved on an SDS-PAGE gel before analysis
by autoradiography. B, RanBPM co-immunoprecipitates with AR. LN-
CaP cells were induced with (lanes 2, 5, and 6) or without (lanes 1, 3,
and 4) 10 nM R1881 for 4 h prior to lysis in radioimmune precipitation
buffer. Whole cell extracts were incubated with normal rabbit IgG
(lanes 3 and 5) or an antibody to the COOH terminus of AR (lanes 4 and
6). Input protein lysates from LNCaP cells grown,  or  R1881, are
shown in lanes 1 and 2, respectively. Proteins were pulled down using
protein A/G coupled to agarose beads and resolved on an 8% SDS-PAGE
gel prior to Western blot with an antibody that recognizes BPM90 (top
panel) or the NH2 terminus of AR (bottom panel). C, the pRC/CMV-
BPML vector was used for in vitro transcription/translation in the
presence of [35S]methionine (top panel). Radiolabeled truncated frag-
ments of BPML were generated by restriction digest of the expression
vector with EcoRI (BPM148–408; middle panel) or NdeI (BPM148–251;
bottom panel) followed by in vitro labeling. The fragments of RanBPM
were incubated with His-AR1–646 for 4 h prior immunoprecipitation
with an anti-His antibody (lane 2) or normal mouse IgG as a negative
control (lane 3). 10% input of the labeled protein is seen in lane 1.
FIG. 3. RanBPM is ubiquitously expressed. A, A multiple tissue
Northern blot (Clontech) was analyzed with a [32P]cDNA probe coding
for RanBPM to determine the size and expression profile of the Ran-
BPM transcript. Tissue samples on the membrane included spleen (lane
1), thymus (lane 2), prostate (lane 3), testes (lane 4), ovaries (lane 5),
small intestine (lane 6), colon (lane 7), and peripheral blood lympho-
cytes (lane 8). B, poly(A) RNA was isolated from four carcinoma cell
lines for Northern blot analysis. 5 g of mRNA from each cell line was
run on a 1% agarose gel with 30% formaldehyde and transferred to a
nylon membrane by capillary action. Samples include PC3 and LNCaP
prostate cancer cell lines (lanes 1 and 2, respectively), the MCF7 breast
carcinoma cell line (lane 3), and a cervical cancer cell line, HeLa (lane
4). The membrane was hybridized with a radiolabeled RanBPM cDNA
probe (top panel). Loading efficiency was normalized with glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (bottom panel). C, RanBPM
protein expression was assessed for the four cancer cell lines described
above. Total protein (50 g) was resolved on a 10% SDS-PAGE gel and
transferred to a polyvinylidene difluoride membrane. Samples include
PC3, LNCaP, MCF7, and HeLa cell lines (lanes 1–4, respectively). An
antibody specific for BPM90 (20) was used for Western blot analysis (top
panel). Protein loading efficiency was normalized by -actin (bottom
panel).
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the androgen receptor at the NH2 terminus and at the DNA-
binding domain (Fig. 2A). To determine whether this interac-
tion has a biological impact on AR activity, transcriptional
assays were carried out using the PC3 cell line. PC3 cells
represent a relatively undifferentiated stage of prostate cancer.
These cells express very little to no androgen receptor and do
not demonstrate androgen-regulated growth. Cells were tran-
siently transfected with an AR expression vector (pCMV/AR6),
the pARR3-tk-Luc reporter plasmid, and increasing amounts of
RanBPM (pcDEB-BPM90) and then were induced in the pres-
ence or absence of 1 nM R1881 for 24 h prior to harvesting for
luciferase assays (Fig. 4A). In the absence of hormone, negligi-
ble AR-mediated transcriptional activity was observed from the
pARR3-tk-Luc reporter plasmid. An addition of hormone re-
sulted in an 9-fold induction of AR activity. In the presence of
hormone, the overexpression of BPM90 resulted in an AR ac-
tivity that was three times greater than in the absence of
RanBPM. AR activity in the absence of hormone was un-
changed by the addition of RanBPM, even with a 20-fold excess
of BPM90 (Fig. 4B). Western blot analysis of cell lysates was
carried out to ensure equivalent levels of AR expression in all
samples (data not shown). Additional transactivation assays
were carried out using an NH2-terminal truncated form of
RanBPM (BPML) in which expression is under the control of a
CMV promoter (Fig. 4A). The presence of BPML increases basal
AR activity by 4-fold when androgens are present. BPML did
not affect the activity of AR in the absence of ligand when the
AR was transcriptionally inactive.
Because RanBPM was identified by its interaction with the
NH2 terminus of the AR, similar transactivation experiments
were carried out with a form of the AR that is deleted for the
LBD, pRC/CMV-AR1–646. This region of the AR has the AF-1
site and is capable of ligand-independent transcriptional activ-
ity. PC3 cells were transiently transfected with the truncated
AR construct and treated with or without 1 nM R1881. AR1–646
is capable of high levels of transcriptional activity both in the
presence and absence of ligand (Fig. 4C). Increasing amounts of
BPM90 resulted in increased AR1–646 activity up to 2.5-times
greater than basal levels. This increase in AR activity was
independent of added hormone.
The ARR3 promoter of the reporter plasmid is a synthetic
highly active promoter that has three ARRs in tandem. The PB
and PSA promoters, however, may be more physiologically
relevant. In vivo, the expression of the rat probasin gene is
restricted to the prostate and is regulated by the AR (21, 25).
PSA gene expression is also regulated by AR activity and is
used as a molecular marker for prostate cancer progression
(26). Luciferase reporter constructs under the control of the PB
and PSA promoters were also used to determine the effect of
BPM90 overexpression on AR activity (Fig. 5, A and B). PC3
cells transfected with pCMV/AR6 and PB-Luc demonstrated a
slight increase in ligand-dependent AR activity in the presence
FIG. 4. RanBPM enhances AR activ-
ity. A, PC3 cells were transfected with
full-length AR (250 ng/well), pARR3-
tk-Luc (167 ng/well), and increasing
amounts of pcDEB-BPM90 or pRC/
CMV-BPML (0, 250, 500, or 2500 ng/well).
DNA was kept constant at 3 g/well by
the addition of empty vector. Transfection
was performed using Lipofectin reagent
(Invitrogen) for 16 h at 37 °C. Cells were
induced in the presence (f) or absence ()
of 1 nM R1881 for 24 h before harvesting
for luciferase assay. B, RanBPM does not
change AR activity in the absence of li-
gand. PC3 cells were transfected with AR
(125 ng/well) and pARR3-tk-Luc (167 ng/
well) and BPM90 at increasing ratios
with AR (0:1, 2:1, 20:1) as described
above. Transfected cells were maintained
in Dulbecco’s modified Eagle’s medium 
5% stripped FBS without additional an-
drogens () or with 1 nM R1881 (f) for
24 h prior to analysis. DNA was kept con-
stant at 3 g/well by the addition of empty
vector. C, RanBPM can enhance the ac-
tivity of a constitutively active fragment
of the AR. AR1–646 encodes the full NH2-
terminal domain and DBD of the AR and
exhibits ligand-independent transactiva-
tion. PC3 cells were transfected with
pRC/CMV-AR1–646 (250 ng/well), pARR3-
tk-Luc, and BPM90 (1, 250, or 2500 ng/
well) as described above. Cells were in-
duced for 24 h at 37 °C with 1 nM R1881 (f)
or with vehicle alone (). For all experi-
ments, Western blot analysis was carried
out on lysates to ensure that AR levels
were constant (data not shown). Transfec-
tion efficiency was normalized with a Re-
nilla luciferase expression vector (pRL-
TK). Values are the average of triplicates.
Each graph is representative of three in-
dependent experiments.
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of BPM90 (Fig. 5A). On the other hand, the overexpression of
BPM90 resulted in a 2-fold increase in ligand-dependent AR
transactivation from the PSA-Luc reporter construct (Fig. 5B).
AR expression levels remained constant under the different
treatments as determined by Western blot (data not shown).
RanBPM Specifically Regulates AR- and GR-mediated
Transactivation—To determine whether RanBPM could en-
hance transactivation of AR alone or of other steroid receptors
as well, transcription assays were carried out with GR, ER-,
and ER-. PC3 cells were transfected with expression plasmids
for GR, ER-, or ER- (250 ng/well) and with increasing
amounts of BPM90 prior to induction with 10 nM Dex or 10 nM
E2, respectively (Fig. 6A). In PC3 cells, GR shows an 11-fold
induction in the presence of 10 nM Dex (Fig. 6A, lane 1). This
activity increases with the overexpression of BPM90 as seen in
Fig. 6A, lane 2. High levels of BPM90 (2.5 g/well) gave a
31-fold induction of GR activity in the presence of Dex (Fig. 6A,
lane 2). Similar to the AR, GR activity was unchanged by high
levels of BPM90 in the absence of ligand (data not shown).
In addition, estrogen receptor was ectopically expressed in
PC3 cells by transient transfection of either the pSMVT:wtER
or pcDNA4-hER1 expression vector (250 ng/well) (Fig. 6A,
lanes 3–6). ER- activity in PC3 cells showed a greater than
1.7-fold induction in the presence of ligand (10 nM E2) (Fig. 6A,
lane 3). This activity was relatively unchanged by the expres-
sion of RanBPM. Even when BPM90 was present at a 10:1 ratio
with the receptor (2500 ng of BPM90/well), ER--mediated
transactivation remained the same (lane 4). Similarly, ER-
showed a 2-fold induction in the presence of 10 nM E2 regard-
less of the presence of BPM90 (Fig. 6A, lanes 5 and 6).
To assess the affect of RanBPM in alternate cell environ-
ments, prostate cancer LNCaP and breast carcinoma MCF7
cell lines were used (Fig. 6, B and C). Cells were transiently
transfected with the expression vector for BPM90 or with
empty vector pcDEB and steroid receptor expression vectors
(250 ng/well) to determine whether RanBPM overexpression
could modify steroid receptor activity. In LNCaP cells, AR has
very high levels of activity when induced with 1 nM R1881 for
24 h (64-fold induction). AR activity was 2.8-times greater
when high levels of BPM90 (2500 ng/well) were expressed in
LNCaP cells as determined by luciferase assay (Fig. 6B). A
similar enhancement of transcriptional activity, 2-fold increase
in the presence of 10 nM Dex, was seen in LNCaPs that were
co-transfected with GR and BPM90 (Fig. 6B). On the other
hand, the difference in either ER- or ER- activity in MCF7
cells in the presence or absence of BPM90 was not statistically
significant (Fig. 6C). These results demonstrate that RanBPM
is able to modify AR and GR activity in at least two different
prostate cancer cell lines but did not influence ER activity in
either prostate or breast cancer cell lines.
DISCUSSION
The mechanism that dictates AR-specific transactivation is
still unclear. Upon ligand binding, the AR translocates to the
nucleus, binds to DNA, and recruits members of the basal
transcription machinery. Unique protein-DNA interactions in
the promoter/enhancer region of AR-regulated genes are one
mechanism by which AR-specific transcriptional regulation
may be attained. Recent studies by Reid et al. (27) show that
the AR interacts with two different classes of androgen recep-
tor response elements in the rat probasin promoter. The ex-
pression of the probasin gene in rats is highly restricted to the
prostate and is regulated by AR. In addition to known interac-
tions between the AR and conventional class I androgen recep-
tor response elements, these studies have demonstrated novel
interactions that occur with a class II androgen receptor re-
sponse elements, which may add specificity to AR transactiva-
tion responses. Other studies have demonstrated that unique
receptor-DNA interactions can occur for different steroid recep-
tors as well (28, 29).
Co-regulatory molecules that interact with AR and the tran-
scription apparatus to enhance or repress gene expression may
also impart a degree of receptor-specific activity. Although
several AR-interacting co-regulatory proteins have been iden-
tified, the majority of these proteins interacts with AR at the
LBD and DBD, which are regions of high homology between
steroid receptor family members. AR and progesterone receptor
share up to 80% homology at the DBD, whereas AR and GR
share 55% homology at the LBD (15). As a result, several
co-regulatory proteins such as steroid receptor co-activator-1,
ARA70, CREB-binding protein/p300), and the SWI/SNF chro-
matin-remodeling proteins are not unique to the AR and have
been shown to interact with other steroid receptors (reviewed
in Ref. 30).
In this study, RanBPM was identified as an AR-binding
protein. An NH2-terminal fragment of the AR (AR1–232) was
used as bait in the yeast two-hybrid assay, and subsequent
GST pull-down assays have confirmed the interaction (Figs. 1
and 2A). Traditionally, the NH2-terminal domain of the AR is
incompatible with yeast two-hybrid assays because of the li-
gand-independent transcriptional activity of the AF-1 domain
(5). However, the AR fragment that was used as bait is trun-
cated for AF-1 and is devoid of transactivation properties.
Furthermore, AR1–232 is of interest because there are no ho-
mologous regions found in other steroid receptors.
RanBPM was originally identified by its interaction with
Ran, a small Ras-like GTPase (19). Although RanBPM was
initially identified as a 55-kDa protein (BPM55), a longer form
has been reported more recently (20). The novel RanBPM pro-
tein, BPM90, is a 90-kDa protein that demonstrates nuclear
and perinuclear localization in HeLa and KB cells lines. The
function of BPM90 is still unclear, but it has recently been
FIG. 5. BPM90 enhances AR activity on multiple AR-regulated
promoters. PC3 cells were transfected as described previously with
full-length AR, the pPB-Luc (A) or pPSA-Luc (B) reporter plasmids (167
ng/well) with the addition () or absence () of pcDEB-BPM90 (2500
ng/well). Relative luciferase units were measured following a 24-h in-
duction with 1 nM R1881 (f) or with vehicle alone (). Transfection
efficiency was normalized with pRL-TK. Values are the average of
triplicates. Each graph is representative of three independent
experiments.
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linked to the Ras/ERK signaling pathway because of its inter-
action with the MET receptor protein tyrosine kinase (31).
The three RanBPM library clones that were isolated in the
yeast-two hybrid assay contain amino acid sequences that are
upstream of the BPM55 start codon but are within the coding
region of BPM90, which suggests that BPM90 interacts with
AR in vivo. This finding was confirmed in LNCaP cells by
co-immunoprecipitation of BPM90 with endogenously ex-
pressed AR (Fig. 2B). A SPRY domain straddles the start codon
of BPM55 such that part of the domain is upstream of the start
codon. Hence, the complete SPRY domain is not present in
BPM55 but is fully intact in BPM90. The SPRY domain, orig-
inally identified in the ryanodine receptor, is involved in pro-
tein-protein interactions (32). It is probable that the SPRY
domain is the region of BPM90 that interacts with the NH2
terminus of the AR. In fact, an NH2-terminal truncation of the
SPRY domain results in the loss of the RanBPM/AR interaction
in yeast (data not shown). The interaction between RanBPM
and AR is also lost when the SPRY domain is truncated at the
COOH-terminal end (Fig. 2C).
RanBPM may also have a role in Ran-dependent nuclear
transport. Ran/ARA24 is a small nuclear Ras-like GTPase that
is ubiquitously expressed (33). Quantitative analysis shows
that 107 molecules of Ran/ARA24 are expressed in an indi-
vidual cell (34). The Ran/ARA24 nuclear import/export path-
way is well defined and uses a RanGTP/GDP gradient along
with carrier proteins to shuttle proteins across the nuclear
membrane (reviewed in Refs. 35 and 36). Interestingly, Ran/
ARA24 was also found to interact with the NH2 terminus of the
AR, suggesting that AR, RanBPM, and Ran/ARA24 work to-
gether as part of a multi-protein complex (34).
The LNCaP co-immunoprecipitation data presented in this
paper show that AR interacts with BPM90 in vivo only in the
presence of ligand when the receptor has been activated (Fig.
2B). Therefore, it is probable that RanBPM and Ran/ARA24
enhance AR activity either by promoting nuclear import of the
activated receptor or by discouraging AR export from the nu-
cleus. These mechanisms are currently under investigation.
The AR1–232 fragment that was used as bait in the yeast
two-hybrid assay contains unique elements such as the long
polymorphic polyglutamine (poly-Gln) and polyglycine (poly-
Gly) repeats (37). The poly-Gln tract is of particular interest
because an inverse relation has been demonstrated between
the length of the poly-Gln tract and AR activity (38), which
suggests that poly-Gln tracts have an important role in direct-
ing AR activity.
Our GST- and His-tagged pull-down assays have demon-
strated that RanBPM interacts directly with AR1–232 and with
larger AR fragments that span the full NH2-terminal domain
(AR1–559) (Fig. 2, A and C). In addition, RanBPM was found to
interact with the DBD of the AR, whereas the LBD did not
contribute to the interaction (Fig. 2C). The overexpression of
BPM90 in the PC3 cell line, which does not express endogenous
AR, along with full-length AR resulted in a 3-fold increase in
androgen-induced AR activity from a synthetic promoter,
pARR3-tk-Luc, above basal AR activity (Fig. 4A). The func-
tional domain of BPM90 is not located at the NH2 terminus
because BPML, which is truncated for the first 147 amino acids
of BPM90, also enhances AR activity (Fig. 4A).
Transcription assays using the full-length AR indicate that
FIG. 6. RanBPM enhances AR- and
GR- but not ER-mediated transacti-
vation. A, PC3 cells were transfected
with GR (lanes 1 and 2), ER- (lanes 3 and
4), or ER- (lanes 5 and 6) (250 ng/well),
appropriate reporter plasmids (pARR3-
tk-Luc for GR and pERE-Luc for ER-
and ER-) (167 ng/well), and increasing
amounts of pcDEB-BPM90 (0, 250, or
2500 ng/well). Cells were induced in the
presence or absence of 10 nM Dex or 10 nM
E2 for cells transfected with GR or ER,
respectively, for 24 h prior to analysis for
luciferase activity. Empty pcDEB was
used to keep DNA levels constant at 3
g/well. Transfection efficiency was nor-
malized with pRL-TK. B, LNCaP cells
were transfected with pCMV/AR6 (lanes 1
and 2) or pGR (lanes 3 and 4) (250 ng/
well) and pARR3-tk-Luc as described pre-
viously. Receptor activity was determined
in the absence () or presence () of pc-
DEB-BPM90 (2500 ng/well). Trans-
fected cells were induced in the presence
of 1 nM R881 for AR, 10 nM Dex for GR, or
vehicle alone for 24 h. Empty vector was
used to ensure that DNA was kept con-
stant at 3 g/well. C, MCF7 cells were
transfected with the ER- or ER- expres-
sion vector and pERE-Luc as described
above and in the absence () or presence
() of pcDEB-BPM90 (2500 ng/well).
Cells were treated with 10 nM E2 or vehi-
cle alone for 24 h prior to analysis for
luciferase activity. DNA content was
maintained at 3 g/well with empty pc-
DEB plasmid. For all experiments, pro-
tein content was used to normalize lucif-
erase results (relative luciferase units/g
protein). Results are expressed at fold in-
duction in the presence of ligand and are
an average of three replicates. Results are
representative of three independent
experiments.
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BPM90-mediated enhancement of AR activity is ligand-
dependent because negligible activity was seen in the absence
of hormone, even at very high levels of BPM90 (Fig. 4B). These
results are consistent with the nuclear localization of BPM90
and suggest that AR must first be activated before RanBPM
can function. The ability of BPM90 to augment AR-mediated
transactivation is not only seen with the artificial ARR3 pro-
moter, which has three ARR motifs in tandem, but also with
the naturally occurring PSA promoter and, to a lesser degree,
the rat probasin promoter (Fig. 5).
Furthermore, it seems probable that the RanBPM is most
likely to influence the transcriptional activity of AF-1, which is
found in the NH2-terminal domain, and not the COOH-termi-
nal AF-2 function. Additional transcriptional assays in PC3
cells using the constitutively active AR, AR1–646, confirm the
role of BPM90 in AF-1 transactivation because enhanced AR
activity was observed irrespective of hormone (Fig. 4C). The
ligand-dependent interaction between AR and BPM90 is con-
firmed because the co-immunoprecipitation from LNCaP cells
only occurs with R1881 treatment (Fig. 2B). These data are
consistent with the role of RanBPM in AR transport across the
nuclear membrane because full-length AR requires activation
by its cognate ligand before translocation, whereas AR1–646 is
targeted to the nucleus even in the absence of hormone.
Although RanBPM interacts with the unique NH2-terminal
domain of the AR, it also interacts with the DBD (Fig. 2A). This
finding suggests that RanBPM can interact with other steroid
receptors as well. Transcription assays carried out in PC3 cells
show that overexpression of BPM90 enhances the transactiva-
tion function of GR, whereas the activity of ER- and ER-
remains unchanged (Fig. 6A). These results demonstrate that
RanBPM selectively amplifies steroid receptor activity. These
results are supported by observations with receptor transacti-
vation assays using LNCaP and MCF7 cell lines (Fig. 6, B and
C). Again, the role of RanBPM in receptor transport is sup-
ported by these data since GR, but neither ER nor ER
requires translocation to the nucleus upon activation. Because
ER- and ER- are already localized in the nucleus (39, 40), the
overexpression of RanBPM is not likely to have an effect on ER
activity.
The data presented here show that BPM90 is capable of
enhancing AR transactivation in a ligand-dependent manner.
Nevertheless, the constitutively active form of AR is also influ-
enced by the overexpression of BPM90. Furthermore, BPM90
influences the activity of GR but has no effect on either ER- or
ER- activity, which suggests that this protein selectively di-
rects steroid receptor activity, possibly at the level of nuclear
transport. Nevertheless, the elucidation of RanBPM function
will provide further insight into the mechanism of AR-medi-
ated gene expression.
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